PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 21, 2026Communications Medicine0 citationsOpen Access

Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments

MTMamoru TakadaSGSakuntha GunarathnaRNRegina Nguyen

Key Points

  • This research aims to understand how abemaciclib works in treating metastatic breast cancer using cfDNA profiling.
  • Analyzed circulating chromatin fragments in patients undergoing treatment with abemaciclib.
  • Profiling cfDNA to assess molecular changes linked to therapy response.
  • Evaluated the potential of cfDNA as a biomarker for treatment monitoring.
  • cfDNA profiling reflects changes in response to targeted therapy.
  • Identified molecular markers that predict therapeutic outcomes.
  • Demonstrated the feasibility of using cfDNA in clinical practice for monitoring.

Abstract

Our findings suggest that cfDNA profiling captures molecular changes induced by targeted therapy and may serve as a practical biomarker for treatment monitoring and prediction of therapeutic response. This research provides insight into the mechanisms of CDK4/6 inhibitor action in metastatic breast cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Takada et al. (2026) studied this question.

synapsesocial.com/papers/69be35166e48c4981c67330fhttps://doi.org/10.1038/s43856-026-01494-w
Ask AI
Helpful
Bookmark
Share
View Full Paper